Sun Pharmaceutical Industries Limited · NSE:SUNPHARMA

Sun Pharmaceutical Industries — Investor Presentation (February 2019)

56 slides from Sun Pharmaceutical Industries's investor presentation, February 2019

  1. Slide 1: Creating Lasting Value

    Creating Lasting Value Investor Presentation – February 2019 NSE:SUNPHARMA | BSE:524715 | Bloomberg:SUNP IN | Reuters:SUN.BO WWW.SUNPHARMA.COM

  2. Slide 2: Disclaimer

    Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “pl

  3. Slide 3: Contents

    Contents 1 Sun Pharma at a glance 2 Long-term Strategy 3 Global Specialty Initiatives 4 Revenue Composition, History & Acquisition Track Record 5 Business Operations, R&D, Manufacturing 6 Corporate Governance 7 Financials – P&L, Balance Sheet, Cash Flows & Ratios 8 Key Milestones Targeted © Sun Phar

  4. Slide 4: Sun Pharma at a glance

    Sun Pharma at a glance 5th Largest Global Specialty Generic Company US • Ranked 6th in US* / Largest Indian Pharma Company in US India • No. 1 Pharma Company in India • Amongst the largest Indian Pharma Company in Emerging Emerging Markets Markets Europe • Expanding presence in Europe Manufacturing

  5. Slide 5: World's 5th Largest Specialty Generic Pharma Co

    World’s 5th Largest Specialty Generic Pharma Co 0.0 2.0 Worldwide 2018 4.0Generic Sales 6.0 8.0 (US$ in billions) 10.0 12.0 Mylan 11.9 Teva 10.3 Novartis 8.9 Pfizer 5.2 Sun Pharma + Taro 3.5 Fresenius 3.0 Endo 2.3 Lupin 2.2 Aurobindo 2.1 Sanofi 2.0 Dr. Reddy 1.7 Apotex 1.6 Zydus Cadila 1.6 STADA 1.5

  6. Slide 6: Sun Pharma today

    Sun Pharma today US Formulations India Branded Generics 6th largest generics company in US* with a strong No.1 ranked with 10 classes of doctor categories pipeline (123 ANDAs & 6 NDAs awaiting approval) Leading position in high growth chronic therapies Presence in generics, Specialty and branded seg

  7. Slide 7: Driving Long Term Growth

    Driving Long Term Growth • Optimize operational costs • Enhance share of specialty business globally • Vertically integrated operations • Achieve differentiation by focusing on technically complex products • Focus on key markets – achieve critical mass • Speed to market • Ensure sustained compliance

  8. Slide 8: Our Specialty Initiatives

    Our Specialty Initiatives • Launched Ilumya (tildrakizumab) in US in Oct’ 18 for the treatment of Moderate-to- Severe Plaque Psoriasis. • Phased launch ILUMETRI® (tildrakizumab) by Almirall in Europe • Initiated clinical trials for two new indications for Ilumya – for psoriatic arthritis and ankylos

  9. Slide 9: Highly Diversified Revenue Base

    Highly Diversified Revenue Base Emerging Markets 19% Western Europe & Other Markets # 11% API & Others 5% India Branded FY18 Sales Formulations Rs.261 billion 31% US Formulations 34% # Includes Western Europe, Canada, Japan , Australia, New Zealand and other markets. © Sun Pharmaceutical Industries

  10. Slide 10: Impressive Track Record of Growth

    Impressive Track Record of Growth (All Figures in INR Billion) 260.7 51.8 35.7 49.1 33.7 112.4 14.9 Adjusted Sales 15.5 EBITDA Net Profit 33.6 CAGR CAGR CAGR 2.8 2.5 8.3 26% 22% 19% FY03 FY08 FY13 FY18 FY03 FY08 FY13 FY18 FY03 FY08 FY13 FY18 25.1 39.1 14.9 19.5 14.0 33.6 Operating Free Cash 6.2 Adju

  11. Slide 11: Consistent profitability and returns

    Consistent profitability and returns Gross Margin # EBITDA Margin Net Margin (adjusted) 83% 45% 35% 75% 77% 73% 72% 29% 29% 23% 27% 18% 19% 20% 13% FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18 ROCE ROE Market Cap (USD Bn) 27% 31% 35 30 25 16% 19% 20% 14% 15% 18% 20 18 8

  12. Slide 12: Profitability

    Profitability Gross Margin EBITDA Margin Net Margin 83% 82% 77% 44% 45% 75% 73% 72% 35% 32% 66% 64% 29% 29% 63% 63% 28% 62% 62% 23% 19% 22% 23% 18% 20% 14% 14% 14% 19% 19% 19% 12% 13% 10% 8% 18% FY13 FY14 FY15 FY16 FY17 FY18 FY13 FY14 FY15 FY16 FY17 FY18 FY13 FY14 FY15 FY16 FY17 FY18 Gross margin= (

  13. Slide 13: Creating Value, Continuously…

    Creating Value, Continuously… • Licensing agreement with Almirall for Tildrakizumab in Europe for Psoriasis • Announced positive results from Phase-3 trials for Tildrakizumab • Launched • Entry into Japan -Acquired 14 brands from Began with 5 Acquired URL Xelpros in Novartis Acquired Taro Acquired D

  14. Slide 14: Key Deals & Rationale

    Key Deals & Rationale Year Deals Country Rationale 2018 Acquired Pola Pharma in Japan Japan Building global dermatology business Acquired global rights for Cequa & 2016 Global Enhances specialty pipeline. Odomzo 2016 Acquired Biosintez Russia Local manufacturing capability to enhance presence in Rus

  15. Slide 15: Successful track record of turning around acquisitions

    Successful track record of turning around acquisitions ROCE 27% 26% 23% 35% 41% 19% 22% 30% 20% 27% 14% 16% 8% 350 8 Early Acquisitions 4 Acquisitions Recent Acquisitions 300 Assets of: Taro Bryan Dusa 250 Hungary URL Able Labs Tildrakizumab Chattem Ranbaxy 200 InSite Vision Ocular Tech 150 Odomzo Y

  16. Slide 16: US Business

    US Business 34% of Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 16

  17. Slide 17: US Business at a glance

    US Business at a glance 6th Largest Pharma Company in the US Generics Market * • Largest generic dermatology company and amongst top 5 Dermatology Segment branded dermatology company in the US • Wide basket of 564 ANDAs & 55 NDAs filed and 441 ANDAs & 49 Comprehensive Portfolio NDAs approved across

  18. Slide 18: US Business - Significant Ramp-up in Sales

    US Business - Significant Ramp-up in Sales Key Milestones in US Sales in Rs billion FY98 • Entry in US through Caraco acquisition 10 year CAGR - 20% • Acquired Taro Pharma – Entry into US FY10 dermatology market 137 135 138 • Acquired DUSA - Entry in branded FY13 specialty market • Acquired InSite V

  19. Slide 19: ANDA Pipeline - Significant ramp up

    ANDA Pipeline - Significant ramp up ANDAs Filed and Approved 441 ANDA Approvals by Therapeutic Area 597 584 572 561 564 115 478 100 449 438 441 413 427 422 344 311 63 46 31 30 19 15 12 10 CNS CVS Oncology Metabolism Gastro Skin Pain Allergy Other Antibiotic FY13 FY14 FY15 FY16 FY17 FY18 Dec-18 Cumul

  20. Slide 20: India Branded Generic Business

    India Branded Generic Business 31% of Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 20

  21. Slide 21: India Business at a glance

    India Business at a glance No. 1 in India Market Position** • No. 1 ranked with 8.2% market share Prescription Ranking## • No. 1 ranked by prescriptions with 10 different classes of doctors Chronic Segment • Market leader in the chronic segment Acute Segment • Strong positioning in the acute segment

  22. Slide 22: Largest Pharma Company in India

    Largest Pharma Company in India Market Share Branded Generic Sales in India as of 12 Months ended Dec 2018 (US$ in mn) 1,362 Sun Pharma 8.2% 1,008 Abbott + Abbott HC + Novo 6.3% 777 Cipla 4.7% 680 Zydus + Biochem 4.1% 590 Lupin 3.7 583 Mankind 3.6% 557 Alkem + Cachet + Indchemie 3.5% 509 Torrent 3.2

  23. Slide 23: India Business – Sales ramp-up

    India Business – Sales ramp-up Leadership in chronic segment; Strong positioning in acute segment 30 brands in top 300 brands of country Sales in Rs Billion Therapeutic Revenue Break-up 10 year CAGR -18% Others Opthalmology 3% 7% Cardiology 80 77 18% Gynaecology, 3% 71 67 Respiratory 4% Vitamins / M

  24. Slide 24: Strong Customer Focus Drives Market Share Gains

    Strong Customer Focus Drives Market Share Gains Therapy focused marketing Strong increase in market share • 9,200+ sales representatives • Sun pharma market share has consistently increased from 2.4% in 2000 to 7.7% in • Covering over 400,000* doctors 2018 (IMS Data for Dec’18) * Does not exclude ov

  25. Slide 25: Leadership in key therapeutic areas

    Leadership in key therapeutic areas* Number 1 Ranking with 10 Doctor Categories* Prescription Ranking Specialist Oct’14 Oct ‘15 Oct ‘16 Oct ‘17 Oct ’18 Psychiatrists 1 1 1 1 1 Neurologists 1 1 1 1 1 Cardiologists 1 1 1 1 1 Orthopaedic 1 1 1 1 1 Gastroenterologists 1 1 1 1 1 Nephrologists 1 1 1 1 1 D

  26. Slide 26: Best-in-class field force productivity

    Best-in-class field force productivity Sales Per Representative (Rs. Mn) Field Force Productivity 11.1 11.0 Impact of Ranbaxy 10.1 Acquisition Sun • Rs 8.6 Mn/ MR Pharma 8.6 8.3 7.8 Industry 7.4 • Rs 5.2 Mn/ MR Average* * Approximation based on brokerage reports • Well trained and scientifically ori

  27. Slide 27: Emerging Markets

    Emerging Markets 18% of Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 27

  28. Slide 28: Emerging Markets Business at a glance

    Emerging Markets Business at a glance Largest Indian Company in Emerging Markets Global footprint • Presence in about 100 markets • Brazil, Mexico, Russia, Romania, South Africa and complementary Focus Markets & affiliated markets Product Portfolio • Extensive basket of branded products Customer Foc

  29. Slide 29: Western Europe, Canada, Japan, ANZ & Other Markets

    Western Europe, Canada, Japan, ANZ & Other Markets 11% of Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 29

  30. Slide 30: Western Europe & Other Markets at a glance

    Western Europe & Other Markets at a glance Amongst the leading Indian Companies • Across all major markets in Western Europe, Canada, A&NZ, Japan Market Presence and few other markets • Expanding basket of products including injectables and hospital Product Portfolio products as well as products for

  31. Slide 31: Global Consumer Healthcare Business

    Global Consumer Healthcare Business © Sun Pharmaceutical Industries Limited. All Rights Reserved. 31

  32. Slide 32: Global Consumer Healthcare Business at a glance

    Global Consumer Healthcare Business at a glance An Attractive Opportunity India • Amongst the top 10 consumer healthcare companies Global Presence • Operates in about 20+ countries • Core markets include. India, Russia, Romania, Nigeria, South Africa & Myanmar Market Focus • Growth markets include U

  33. Slide 33: Active Pharmaceutical Ingredients (API) Business

    Active Pharmaceutical Ingredients (API) Business 6% of Revenues © Sun Pharmaceutical Industries Limited. All Rights Reserved. 33

  34. Slide 34: API Business

    API Business Backward Integration – Strategic Importance • Backward integration provides cost competitiveness and supply Strategic Importance reliability Customers • Large generic and innovator companies Product Portfolio • Approximately 300 APIs Pipeline Development • Approx. 20 APIs scaled up annu

  35. Slide 35: Research & Development

    Research & Development © Sun Pharmaceutical Industries Limited. All Rights Reserved. 35

  36. Slide 36: Research & Development

    Research & Development Cumulative R&D Spend of over Rs 146 billion to date • R&D spend at 8.6% of sales for FY18 R&D Spend • Strong cash flows & large scale to support R&D investments • Strong research teams in generics, finished dosage development, Capabilities biological support, chemistry • Appro

  37. Slide 37: R&D Investments

    R&D Investments R&D Investments Filings and Approvals 5.6% 6.3% 6.5% 7.2% 8.3% 7.6% 8.6% ANDA NDA/BLA DMF/CEP Patents 23.0 23.1 22.5 564 408 1090 55 19.6 49 950 441 303 10.4 7.0 4.4 FY12 FY13 FY14 FY15 FY16 FY17 FY18 Filed Approved Filed Approved Filed Approved Filed Granted R&D Investments (Rs Bn)

  38. Slide 38: Global Manufacturing Presence

    Global Manufacturing Presence © Sun Pharmaceutical Industries Limited. All Rights Reserved. 38

  39. Slide 39: Global Manufacturing Presence

    Global Manufacturing Presence World Class Manufacturing Infrastructure • 44 manufacturing facilities across India, the Americas, Asia, Africa, Extensive Global Footprint Australia and Europe • Vertically integrated network across six continents enabling high Integrated Network quality, low cost and

  40. Slide 40: Global Manufacturing Footprint

    Global Manufacturing Footprint Tiszavasvari Haifa Penza (Hungary) (Israel) (Russia) Ontario (Canada) Cluj (Romania) (US) Giza, (Egypt) Billerica, MA New Jersey(US) Saitama, Japan Lagos (Nigeria) (2 units) Tennessee Kuala Lumpur Be-Tabs, South Africa) (Malaysia) Cranbury Bangladesh Plant Port Fairy (

  41. Slide 41: Finished Dosage Manufacturing

    Finished Dosage Manufacturing 30 Finished dosage manufacturing sites • India : 14, US : 4, Japan : 2 • Canada, Hungary , Israel, Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria and Russia : 1 each • Capacities available for a variety of finished dosages Orals Injectables / Sterile Topica

  42. Slide 42: API Manufacturing

    API Manufacturing 14 API manufacturing locations • India : 9, Australia : 2, Israel : 1, US : 1, Hungary : 1 Panoli & Ahmednagar Australia, Hungary & (both India) Tennessee (US) • International regulatory approvals: USFDA, API • Controlled substances European Key Plants manufacture • Stand alone uni

  43. Slide 43: Corporate Governance

    Corporate Governance Our philosophy on corporate governance envisages working towards high levels of transparency, accountability and consistent value systems across all facets of operations Chairman Israel Makov Former President & CEO of Teva Pharma. Industries Ltd. Independent Director Independent

  44. Slide 44: Financials

    Financials © Sun Pharmaceutical Industries Limited. All Rights Reserved. 44

  45. Slide 45: Financials

    Financials Market Capitalisation Rs. 1,070 billion / US$ 15 billion ( All Figures in Rs. Mn ) FY14 YoY FY15 YoY FY16 YoY FY17 YoY FY18 YoY P&L Summary Sales 1,60,044 42% 2,72,451 70% 2,78,881 2% 3,02,642 9% 2,60,659 -14% Gross Profit 1,32,250 44% 2,05,059 55% 2,15,577 5% 2,21,335 3% 1,86,413 -16% EB

  46. Slide 46: Sales Break-up

    Sales Break-up In INR Billion In USD Million Sales 279 303 261 4,262 4,511 4,044 245 16 225 385 15 26 330 229 22 15 675 461 45 548 36 30 751 48 2066 2051 138 135 1357 87 77 80 1093 1155 1246 71 FY16 FY17 FY18 FY16 FY17 FY18 India Formulations US Formulations #Exchange Rate : US$1 = Rs 65.43 (for FY1

  47. Slide 47: EBITDA Trend

    EBITDA Trend In INR Billion Sales 112 160 272 279 303 261 % of Sales 19% 17% 25% 23% 27% 28% 14% 13% 16% 17% 16% 21% 24% 25% 30% 33% 28% 31% 44% 44% 29% 27% 29% 20% FY13 FY14 FY15 FY16 FY17 FY18 EBITDA Other Expenditure Personnel Costs Material Costs © Sun Pharmaceutical Industries Limited. All Righ

  48. Slide 48: Cash Flow

    Cash Flow Net Cash From Operating Activities (Rs Bn) Free Cash Flow (Rs Bn) 71 34 67 33 33 31 56 25 40 39 20 34 FY13 FY14 FY15 FY16 FY17 FY18 FY13 FY14 FY15 FY16 FY17 FY18 © Sun Pharmaceutical Industries Limited. All Rights Reserved. 48

  49. Slide 49: Financial Ratios

    Financial Ratios FY14 FY15 FY16 FY17 FY18 Grow th (%) Sales 42.4 70.2 2.4 8.5 (13.9) Gross Profit 44.4 55.1 5.1 2.7 (15.8) EBITDA 45.0 8.5 (2.1) 16.1 (40.9) Net Profit 5.3 44.5 0.1 53.2 (69.0) Net Profit (Adjusted) 58.7 # (15.6) # 9.5 # 33.1 (51.7) # Margins (%) Gross Margin 82.6 75.3 77.3 73.1 71.5

  50. Slide 50: Key Financials Q3 & 9mFY19

    Key Financials Q3 & 9mFY19 ( All Figures in Rs. Mn ) Q3 FY19 Q3 FY18 CHANGE 9m FY19 9m FY18 CHANGE Gross Sales 76,567 65,982 16.0% 2,16,420 1,93,549 11.8% Gross Profit 54,911 44,985 22.1% 1,56,118 1,37,003 14.0% Gross Margin 71.7% 68.2% 72.1% 70.8% EBITDA 20,694 13,984 48.0% 50,308 37,672 33.5% EBIT

  51. Slide 51: Sales Breakup Q3 & 9mFY19

    Sales Breakup Q3 & 9mFY19 ( All Figures in Rs. Mn ) Q3 FY19 Q3 FY18 CHANGE 9m FY19 9m FY18 CHANGE Formulation India 22,353 20,850 7% 62,470 60,667 3% US 26,059 21,242 23% 75,475 63,750 18% Emerging Markets 14,618 12,212 20% 41,425 35,598 16% ROW 8,981 7,766 16% 23,774 22,304 7% Sub-total 72,010 62,0

  52. Slide 52: Key Milestones targeted for future

    Key Milestones targeted for future • Enhance share of specialty/branded business US • Continue to focus on complex generics and high entry barrier segments Business • Ensure broad product offering to customers across multiple dosage forms • Improve productivity of India business India • Maintain lea

  53. Slide 53: Key Milestones targeted for future

    Key Milestones targeted for future Global Consumer • Maintain leadership in existing markets through focus on innovative solutions • Enhance presence in high growth markets Healthcare • Focus on developing complex products across multiple dosage forms R&D • Invest to further build on specialty pipel

  54. Slide 54: FY19 Guidance

    FY19 Guidance Consolidated Revenues • Low double digit growth over FY18 R&D Investments • Approximately 7%-7.5% of revenues to be invested in R&D Investing for Future • Invest in R&D and in building the specialty business © Sun Pharmaceutical Industries Limited. All Rights Reserved. 54

  55. Slide 55: Sun Pharma at a glance

    Sun Pharma at a glance 5th Largest Global Specialty Generic Company US • Ranked 6th in US* / Largest Indian Pharma Company in US India • No. 1 Pharma Company in India • Amongst the largest Indian Pharma Company in Emerging Emerging Markets Markets Europe • Expanding presence in Europe Manufacturing

  56. Slide 56: Thank You

    Thank You! For more information please contact: Investors: Nimish Desai Thank You Tel : +91 22 4324 4324, Ext 2778 Tel Direct +91 22 43242778 nimish.desai@sunpharma.com Corporate Address: SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063 © 2017 Sun Pharmaceutical Indus

Sun Pharmaceutical Industries — Investor Presentation (February 2019) on 6ix